ANMCO/SICI-GISE paper on antiplatelet therapy in acute coronary syndrome
- De Luca L.
- Bolognese L.
- Valgimigli M.
- Ceravolo R.
- Danzi G. B.
- Piccaluga E.
- Rakar S.
- Cremonesi A.
- Bovenzi F. M.
- Abbate R.
- Andreotti F.
- Biondi-Zoccai G.
- Capodanno D.
- Caporale R.
- Capranzano P.
- Carrabba N.
- Casella G.
- Cavallini C.
- Colombo P.
- Conte M. R.
- Cordone S.
- Del Pinto M.
- De Servi S.
- Di Lorenzo E.
- Di Pasquale G.
- Esposito G.
- Farina R.
- Fiscella A.
- Formigli D.
- Galli S.
- Giudice P.
- Gonzi G.
- Greco C.
- Grieco N. B.
- La Vecchia L.
- Lazzari M.
- Lettieri C.
- Lettino M.
- Limbruno U.
- Lupi A.
- Macchi A.
- Marini M.
- Marzilli M.
- Montinaro A.
- Musumeci G.
- Navazio A.
- Olivari Z.
- Oltrona Visconti L.
- Oreglia J. A.
- Ottani F.
- Parodi G.
- Pasquetto G.
- Patti G.
- Perkan A.
- Perna G. P.
- Piscione F.
- Prati F.
- Ravasio R.
- Ronco F.
- Rossini R.
- Rubboli A.
- Saia F.
- Sardella G.
- Satullo G.
- Savonitto S.
- Sbarzaglia P.
- Scorcu G.
- Signore N.
- Tarantini G.
- Terrosu P.
- Testa L.
- Tubaro M.
- Valente S.
- Varbella F.
- Vatrano M.
DOIAbstract
Antiplatelet therapy is the cornerstone of the pharmacologic management of patients with acute coronary syndrome (ACS). Over the last years, several studies have evaluated old and new oral or intravenous antiplatelet agents in ACS patients. In particular, research was focused on assessing superiority of two novel platelet adenosine diphosphate (ADP) P2Y12receptor antagonists (i.e. prasugrel and ticagrelor) over clopidogrel. Several large randomized controlled trials have been undertaken in this setting and a wide variety of pre-specified and post hoc analyses are available that evaluated the potential benefits of novel antiplatelet therapies in different subsets of patients with ACS. The aim of this document is to review recent data on the ...
Add to ORKG